Evidence to Recommendations Frameworks
The following are the Evidence to Recommendations (EtR) frameworks that describe information considered in moving from evidence to ACIP vaccine recommendations.
The purpose of EtR frameworks is to help panels making recommendations move from evidence to decisions, and to provide transparency around the impact of additional factors on deliberations when considering a recommendation. These tables accompany ACIP recommendations published in the Morbidity and Mortality Weekly Reports (MMWR).
List of Evidence to Recommendations Framework Tables
Listed in most recently published order.
- ACIP Evidence to Recommendations for Use of Pfizer-BioNTech COVID-19 Vaccine under an Emergency Use Authorization
Linked from MMWR; December 13, 2020 / 69 - EtR Framework for MenACWY-TT (MenQuadfi) Meningococcal Vaccine
Linked from MMWR; September 25, 2020 / 69(9);1–41 - EtR Framework for Serogroup B Meningococcal Vaccine Booster Dose
Linked from MMWRexternal icon; September 25 / 69(9);1–41 - EtR Framework for Serogroup B Meningococcal Vaccine Booster Dose During an Outbreak
Linked from MMWR; September 25 / 69(9);1–41 - EtR Framework for Hepatitis A Vaccine Catch-up
Linked from MMWR; July 3, 2020 / 69(5);1–38 - EtR Framework for Hepatitis A Vaccine for Persons With HIV
Linked from MMWR; July 3, 2020 / 69(5);1–38 - EtR Framework for Tdap Vaccines in Adolescents and Adults
Linked from MMWR; January 24, 2020 / 69(3);77–83 - EtR Framework for PCV13 use among adults ≥65 years old
Linked from MMWR; November 22, 2019 / 68(46);1069–75 - EtR Framework for HPV Vaccination of Adults, Ages 27 through 45 years
Linked from MMWR; August 16, 2019 / 68(32);698–702 - EtR Framework for HPV Vaccination Harmonization across Genders, Ages 22 through 26 years
Linked from MMWR; August 16, 2019 / 68(32);698–702 - EtR Framework for Japanese Encephalitis Vaccine
Linked from MMWR; July 19, 2019 / 68(2);1–33
Page last reviewed: September 24, 2020
Content source: National Center for Immunization and Respiratory Diseases